COMPOSITION CONTAINING ANTIBODY AGAINST ABETA PROTOFIBRILS AND INHIBITOR OF BETA-SECRETASE BACE1 FOR TREATMENT OF ALZHEIMER'S DISEASE Russian patent published in 2022 - IPC A61K31/542 A61K39/395 A61P25/28 

FIELD: pharmaceutics; medicine.

SUBSTANCE: object 1 is a method for the treatment of Alzheimer’s disease, including administration to a subject who needs it of a combination of therapeutically effective amount of an antibody against Aβ protofibrils and therapeutically effective amount of N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazine-7a-yl)-4-fluorphenyl]-5-difluormethylpyrazine-2-carboxamide and/or its pharmaceutically acceptable salt. Object 2 is a combination for use in the treatment of Alzheimer’s disease, containing an antibody against Aβ protofibrils and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazine-7a-yl)-4-fluorphenyl]-5-difluormethylpyrazine-2-carboxamide and/or its pharmaceutically acceptable salt.

EFFECT: reduction in a level of Aβ42 in the brain and increase in power of electroencephalograms in ranges α1 (11-13 Hz) and β1 (13-22 Hz) with administration of a combination.

7 cl, 2 dwg, 2 tbl, 4 ex